CEMIPLIMAB
Manner of administration:Injection
Restriction
Indication: Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 350 mg | # of repeats: 7 | DPMA: $7,528.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Libtayo
(cemiplimab 350 mg/7 mL injection, 7 mL vial)
|
||||